Effect of Restoration of Microrna-18A on Improvement of Imatinib Therapy on Secondary Imatinib-Resistance Metastatic Melanoma.

Jun Guo,Yan Kong,Long Liang,Yiqian Li,Xiao Wei Xu,Lu Si,Zhihong Chi,Chuan Liang Cui,Xi Nan Sheng,Jie Dai

DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.9040

IF: 45.3

2014-01-01

Journal of Clinical Oncology

Abstract:9040 Background: Imatinib generated remarkable clinical response in melanomas harboring c-kit mutation. However, melanoma resistance to imatinib develops rather quickly in most of the patients. It has been shown that gene mutations, translocations, deletions, amplifications, and epigenetic changes are involved in the process of secondary imatinib-resistance in GI stromal tumor. But imatinib resistance in melanoma has not been well evaluated. Methods: The level of miRNAs expression was initially discovered through miRNA profiling using pretreatment and post treatment imatinib resistant melanoma tissues, and then confirmed by quantitative PCR. Scratch wound and in vitro invasion assays were performed to evaluate cell migration and invasion. Luciferase reporter assays, immunoblots, and immunohistochemistry analyses were conducted to examine the association between miR-18a and their targets in imatinib-resistant cell and specimens. Results: miR-18a was dramatically down-regulated in secondary imatinib-resistant melanoma tissues. Reintroduction of miR-18a led to imatinib-resistant cells become sensitive to imatinib treatment. Cell cycle and apoptosis analysis indicated that miR-18a overexpression in combination with imatinib treatment resulted in a decrease of cell numbers of S-phase and an increase of apoptotic cells, respectively. Wound healing assay and in vitro invasion assay indicated enforced expression of miR-18a, as well as imatinib treatment dampened the capacity of melanoma cell migration and metastasis. CCND2 and Notch2 were validated as bona fide effectors of miR-18a in melanoma cells. Furthermore, rescued assay was performed to probe the interaction among miR-18a, CCND2/Notch2, and phenotypic alterations, which demonstrated that the sensitivity of imatinib therapy on imatinib-resistant cell line was improved through miR-18a mediated regulation of CCND2/Notch2. Conclusions: Targeting of miR-18a is sufficient to enhance the therapeutic effect of imatinib on melanoma treatment, suggesting that restoration of miR-18a may be a promising strategy for the prevention of melanoma patients from developing secondary resistance.